Cutaneous melanoma, the most aggressive form of skin cancer, is characterized by its accumulation of a large number of ...

This Phase 2 trial aims to assess the safety, tolerability, and foralumab’s effect on microglial activation in patients with na-SPMS. Intranasal foralumab offers a novel approach to potentially ...

State Key Laboratory of Coordination Chemistry, School of Chemistry and Chemical Engineering, Chemistry and Biomedicine Innovation Center (ChemBIC), ChemBioMed Interdisciplinary Research Center, ...

A generation ago, a diagnosis of multiple sclerosis often meant a steady decline in quality of life. The autoimmune disease, which affects nearly a million people in the U.S., causes the immune ...

Novel therapies are unmet needs in multiple myeloma (MM). Monoclonal antibody (mAb)-based immunotherapy is an emerging field in MM. Clinical efficiency of most therapeutic antibodies is based on ...

This research presents a review of circulating cell-free DNA essential role in the early diagnosis and immunotherapy of pancreatic cancer. The detection methods of cfDNA, its potential as a diagnostic ...

The final, formatted version of the article will be published soon. The intricate interaction between skeletal muscle biomechanics, the tumor microenvironment, and immunotherapy constitutes a pivotal ...

These findings have implications for leveraging ERVs for cancer immunotherapy. Cell. 2025 Feb 25 [Epub ahead of print] Qinqin Jiang, David A Braun, Karl R Clauser, Vijyendra Ramesh, Nitin H Shirole, ...

However, injectable immunotherapy hasn't worked for food allergies ... peanut-containing candies (such as M&Ms), and peanut-containing puffs (like Bamba) from the U.S. and the European Union ...

A simple treatment algorithm may help reduce treatment disparities for Hispanic and Black people with multiple sclerosis (MS), according to a preliminary study released today, March 3, 2025 ...

Multiple sclerosis isn’t inherited, but having a family member with the disease can increase your chance of having the condition. While genetics influences your risk, environmental factors also ...

Patients received omalizumab with placebo oral immunotherapy or vice versa. 88% of the omalizumab group and 51% of the OIT group completed treatment. There were no serious adverse events with ...